{"id":"lemborexant-tablets","safety":{"commonSideEffects":[{"rate":"10%","effect":"Headache"},{"rate":"8%","effect":"Nausea"},{"rate":"6%","effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL3545367","moleculeType":"Small molecule","molecularWeight":"410.42"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Lemborexant is a dual orexin receptor antagonist that has been shown to improve sleep quality and reduce symptoms of insomnia.","oneSentence":"Treats insomnia by modulating orexin receptors","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:42:01.496Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Insomnia"}]},"trialDetails":[{"nctId":"NCT05463861","phase":"PHASE4","title":"Lemborexant in Delayed Sleep Phase Syndrome","status":"COMPLETED","sponsor":"Stanford University","startDate":"2022-02-01","conditions":"Delayed Sleep Phase Syndrome","enrollment":71},{"nctId":"NCT07417813","phase":"","title":"A Multicenter Observational Study of Lemborexant on Insomnia Patients With Psychiatric Disorders","status":"RECRUITING","sponsor":"Shanghai Mental Health Center","startDate":"2026-01-24","conditions":"Insomnia, Psychiatric Disorders","enrollment":121},{"nctId":"NCT07407400","phase":"PHASE4","title":"Lemborexant for Sleep and Delirium Prevention in Elderly ICU Patients","status":"NOT_YET_RECRUITING","sponsor":"Mahidol University","startDate":"2026-04-01","conditions":"Sleep Disturbance, Delirium, Critical Illness","enrollment":100},{"nctId":"NCT05344443","phase":"PHASE4","title":"Lemborexant Shift Work Treatment Study","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2022-03-10","conditions":"Shift-Work Related Sleep Disturbance","enrollment":29},{"nctId":"NCT06823752","phase":"PHASE2","title":"A Dual Orexin Receptor Antagonist to Reduce Biomarkers of Neurodegeneration in Adults With Insomnia.","status":"RECRUITING","sponsor":"Woolcock Institute of Medical Research","startDate":"2025-05-13","conditions":"Insomnia","enrollment":20},{"nctId":"NCT05763329","phase":"PHASE1, PHASE2","title":"Effects of Lemborexant as a Treatment for Moderate-to-severe OSA Patients With Low Arousal Threshold","status":"COMPLETED","sponsor":"Chulalongkorn University","startDate":"2023-02-01","conditions":"OSA","enrollment":10},{"nctId":"NCT06231641","phase":"PHASE2","title":"The Effects of Lemborexant on the Ability to Sleep During Daytime","status":"RECRUITING","sponsor":"Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal","startDate":"2024-01-11","conditions":"Shift-Work Sleep Disorder","enrollment":24},{"nctId":"NCT05594589","phase":"PHASE2","title":"A Study to Assess the Pharmacodynamics of Lemborexant in Korean Participants With Insomnia Disorder","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2022-11-30","conditions":"Sleep Initiation and Maintenance Disorders","enrollment":65},{"nctId":"NCT06874855","phase":"PHASE4","title":"Lemborexant in Delayed Sleep Phase Syndrome","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2023-03-13","conditions":"Delayed Sleep Phase Syndrome","enrollment":15},{"nctId":"NCT06648681","phase":"PHASE2","title":"Lemborexant to Prevent Post-operative Delirium in Cardiac Surgery Patients","status":"NOT_YET_RECRUITING","sponsor":"University of British Columbia","startDate":"2025-05-01","conditions":"Delirium - Postoperative, Cardiac Surgery, Cardiac Surgery Subjects","enrollment":60},{"nctId":"NCT04549168","phase":"PHASE3","title":"A Study of Lemborexant in Chinese Participants With Insomnia Disorder","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2020-11-06","conditions":"Sleep Initiation and Maintenance Disorders","enrollment":194},{"nctId":"NCT02783729","phase":"PHASE3","title":"Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1)","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2016-05-31","conditions":"Insomnia","enrollment":1006},{"nctId":"NCT04647383","phase":"PHASE1","title":"A Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Participants With Moderate to Severe Obstructive Sleep Apnea, and in Adult and Elderly Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2021-01-06","conditions":"Sleep Apnea, Obstructive, Pulmonary Disease, Chronic Obstructive, Respiration Disorders","enrollment":63},{"nctId":"NCT04573556","phase":"","title":"A Study to Evaluate the Safety of DAYVIGO (Lemborexant) Tablets in Participants With Insomnia.","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2020-10-17","conditions":"Sleep Initiation and Maintenance Disorders","enrollment":550},{"nctId":"NCT04890561","phase":"PHASE1","title":"A Study to Evaluate Lemborexant in Milk of Healthy Lactating Women","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2021-05-17","conditions":"Healthy Volunteers","enrollment":8},{"nctId":"NCT04555733","phase":"PHASE1","title":"A Single and Multiple Dose Study of Lemborexant in Healthy Chinese Participants","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2020-10-26","conditions":"Healthy Volunteer","enrollment":26},{"nctId":"NCT03001557","phase":"PHASE2","title":"Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2016-12-20","conditions":"Irregular Sleep-Wake Rhythm Disorder","enrollment":63},{"nctId":"NCT04009577","phase":"PHASE3","title":"A Study to Evaluate Next-Dose Transition From Zolpidem to Lemborexant (LEM) for the Treatment of Insomnia","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2019-07-15","conditions":"Insomnia","enrollment":53},{"nctId":"NCT03158025","phase":"PHASE1","title":"A Study to Determine the Abuse Potential of Single Oral Doses of Lemborexant Compared to Zolpidem, Suvorexant and Placebo in Healthy, Non-Dependent, Recreational Sedative Users","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2017-04-19","conditions":"Insomnia Disorders","enrollment":39},{"nctId":"NCT03440424","phase":"PHASE1","title":"Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2018-01-26","conditions":"Hepatic Impairment","enrollment":24},{"nctId":"NCT03443063","phase":"PHASE1","title":"Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Normal Renal Function or With Severe Renal Impairment","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2018-02-07","conditions":"Renal Impairment","enrollment":16},{"nctId":"NCT03471871","phase":"PHASE1","title":"Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Healthy Subjects and Adult and Elderly Subjects With Mild Obstructive Sleep Apnea","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2018-02-21","conditions":"Obstructive Sleep Apnea, Healthy Subjects","enrollment":146},{"nctId":"NCT02952820","phase":"PHASE3","title":"Long-term Study of Lemborexant in Insomnia Disorder (SUNRISE 2)","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2016-11-15","conditions":"Insomnia Disorder","enrollment":971},{"nctId":"NCT01463098","phase":"PHASE1","title":"A 2-Part Single Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2011-10-05","conditions":"Insomnia","enrollment":122},{"nctId":"NCT02350309","phase":"PHASE1","title":"Study to Evaluate the Effect of 2 Dosage Strengths of Lemborexant (E2006) on a Multiple Sleep Latency Test in Participants With Insomnia Disorder","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2014-12-13","conditions":"Insomnia Disorder","enrollment":69},{"nctId":"NCT03008447","phase":"PHASE1","title":"Crossover Study to Evaluate the Effect of Lemborexant Versus Placebo and Zolpidem on Postural Stability, Auditory Awakening Threshold, and Cognitive Performance in Healthy Subjects 55 Years and Older","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2016-11-21","conditions":"Healthy Subjects","enrollment":60},{"nctId":"NCT03483636","phase":"PHASE1","title":"Study of Lemborexant-Alcohol Interaction in Healthy Subjects","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2018-03-12","conditions":"Healthy Subjects","enrollment":24},{"nctId":"NCT02583451","phase":"PHASE1","title":"Study to Evaluate the Effect of Lemborexant Versus Placebo on Driving Performance in Healthy Adult and Elderly Subjects","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2015-11","conditions":"Healthy Participants","enrollment":48},{"nctId":"NCT03451110","phase":"PHASE1","title":"Study to Assess the Pharmacokinetic Drug-Drug Interactions of Lemborexant When Coadministered With an Oral Contraceptive, Famotidine, or Fluconazole in Healthy Subjects","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2018-02-05","conditions":"Healthy Subjects","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["E2006"],"phase":"phase_2","status":"active","brandName":"Lemborexant tablets","genericName":"Lemborexant tablets","companyName":"Shanghai Mental Health Center","companyId":"shanghai-mental-health-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Treats insomnia by modulating orexin receptors Used for Insomnia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}